News

Part one was a randomized two-way crossover comparison study in 12 healthy subjects to test the pharmacokinetics, safety and tolerability of the original active pharmaceutical ingredient in capsule

Since January 2008, D’Agostino has been serving as Milestone’s acting CFO. Before joining Milestone, D’Agostino served as senior vice president and treasurer of Summit Global Logistics, a publicly

Elesclomol is a novel, oxidative stress inducing, small molecule drug candidate currently undergoing Phase III clinical investigation in metastatic melanoma, the Symmetry trial, with other trials in other

The study validates the company’s CellOptics platform and proprietary digital microscope, the Ikoniscope, as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC)

The transition to Integra Spine will align the spinal implant business more closely with the Integra corporate brand. Integra LifeSciences has previously acquired the Theken companies, which includes

Par has earlier announced a resizing of its generic business as part of an ongoing strategic assessment of the overall business. Mr Martino will stay on through the

Lilly and ImClone have previously announced that they had reached a definitive merger agreement for Lilly to acquire ImClone. There is no financing condition to the tender offer.

The Blair-Port Wand is a critical component of the company’s patented and FDA-approved surgical sponge detection system. Prior to beginning closing procedures, a surgical patient is scanned with

Under the terms of the agreement, Coda will utilize its proprietary suite of technologies to create highly diverse and complex libraries of synthetic genes and proteins for Genencor.